Tags

Type your tag names separated by a space and hit enter

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
Neurogastroenterol Motil 2003; 15(1):79-86NM

Abstract

The 5HT3 receptor antagonist alosetron has been tested in several trials on irritable bowel syndrome (IBS) patients. The aim of the present meta-analysis was to determine its effect on adequate relief of pain or global improvement of symptoms in IBS patients. Six large, multicentre, randomized, placebo-controlled trials fulfilled pre-set criteria for high quality and were included in the meta-analysis; 1762 patients were randomized to alosetron treatment and 1356 to placebo. Seventy-five per cent of the patients experienced diarrhoea-predominant IBS and 93% were females. The pooled odds ratio for adequate relief of pain or global symptoms improvement was 1.81 [95% confidence interval (CI) 1.57-2.10). The average number of patients needed to treat with alosetron for one patient to achieve improvement over placebo treatment was seven (95% CI 5.74-9.43). The present analysis shows that alosetron 1 mg b.i.d. positively impacts global symptoms, and pain and discomfort in non-constipated IBS female patients. One in four patients treated with alosetron may develop constipation. The efficacy of alosetron is unclear in male patients.

Authors+Show Affiliations

Clinical Enteric Neuroscience, Translational & Epidemiological Research Program, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12588472

Citation

Cremonini, F, et al. "Efficacy of Alosetron in Irritable Bowel Syndrome: a Meta-analysis of Randomized Controlled Trials." Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society, vol. 15, no. 1, 2003, pp. 79-86.
Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil. 2003;15(1):79-86.
Cremonini, F., Delgado-Aros, S., & Camilleri, M. (2003). Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society, 15(1), pp. 79-86.
Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of Alosetron in Irritable Bowel Syndrome: a Meta-analysis of Randomized Controlled Trials. Neurogastroenterol Motil. 2003;15(1):79-86. PubMed PMID: 12588472.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. AU - Cremonini,F, AU - Delgado-Aros,S, AU - Camilleri,M, PY - 2003/2/18/pubmed PY - 2003/5/8/medline PY - 2003/2/18/entrez SP - 79 EP - 86 JF - Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society JO - Neurogastroenterol. Motil. VL - 15 IS - 1 N2 - The 5HT3 receptor antagonist alosetron has been tested in several trials on irritable bowel syndrome (IBS) patients. The aim of the present meta-analysis was to determine its effect on adequate relief of pain or global improvement of symptoms in IBS patients. Six large, multicentre, randomized, placebo-controlled trials fulfilled pre-set criteria for high quality and were included in the meta-analysis; 1762 patients were randomized to alosetron treatment and 1356 to placebo. Seventy-five per cent of the patients experienced diarrhoea-predominant IBS and 93% were females. The pooled odds ratio for adequate relief of pain or global symptoms improvement was 1.81 [95% confidence interval (CI) 1.57-2.10). The average number of patients needed to treat with alosetron for one patient to achieve improvement over placebo treatment was seven (95% CI 5.74-9.43). The present analysis shows that alosetron 1 mg b.i.d. positively impacts global symptoms, and pain and discomfort in non-constipated IBS female patients. One in four patients treated with alosetron may develop constipation. The efficacy of alosetron is unclear in male patients. SN - 1350-1925 UR - https://www.unboundmedicine.com/medline/citation/12588472/Efficacy_of_alosetron_in_irritable_bowel_syndrome:_a_meta_analysis_of_randomized_controlled_trials_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1350-1925&date=2003&volume=15&issue=1&spage=79 DB - PRIME DP - Unbound Medicine ER -